Elsevier

Clinical Therapeutics

Volume 19, Issue 4, July–August 1997, Pages 675-690
Clinical Therapeutics

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study

https://doi.org/10.1016/S0149-2918(97)80092-6Get rights and content

Abstract

The efficacy of the oral leukotriene-receptor antagonist zafirlukast was assessed as maintenance therapy for patients with mild-to-moderate asthma. A total of 762 patients aged 12 to 76 years were enrolled in a 13-week, multicenter, double-masked, placebo-controlled, parallel-group trial and randomly assigned to receive either zafirlukast (20 mg twice daily) or placebo. Patients were maintained on as-needed beta-agonist therapy throughout the study and had to have a cumulative daytime asthma symptoms score ≥8 (on a daily scale of 0 to 3) over 7 consecutive days before randomization. Efficacy was assessed by changes in symptoms, beta-agonist use, and pulmonary function. Safety was assessed by adverse experiences, laboratory test results, physical examination, and electrocardiography. Zafirlukast significantly decreased daytime asthma symptoms scores (−26.5%), nighttime awakenings (−19.8%), mornings with asthma (−29.0%), and beta-agonist use (−22.3%) and significantly increased morning peak expiratory flow rate (6.9%) and forced expiratory volume in 1 second (6.3%) compared with placebo. Changes in symptoms, beta-agonist use, and pulmonary function occurred within 2 days of zafirlukast treatment and continued throughout the trial. Zafirlukast was well tolerated. Pharyngitis and headache were the most common adverse events, occurring with similar frequency in both the zafirlukast and placebo groups. No clinically significant changes were observed in laboratory test results, findings on physical examination, or electrocardiographic findings. We conclude that zafirlukast produces early and sustained effects in the treatment of mild-to-moderate asthma.

References (20)

There are more references available in the full text version of this article.

Cited by (155)

  • Leukotriene D<inf>4</inf> role in allergic asthma pathogenesis from cellular and therapeutic perspectives

    2020, Life Sciences
    Citation Excerpt :

    Zafirlukast antagonizes LTD4- and exercise-induced bronchoconstriction [129]. Results from placebo-controlled trial showed that zafirlukast produced early and sustained effects in the treatment of mild-to-moderate asthma [130]. A clinical study showed that LTD4 inhalation causes bronchoconstriction in asthmatics on maintenance inhaled corticosteroid therapy and a single dose of zafirlukast inhibited this mediated effect [131].

  • Development of smart cell-free and cell-based assay systems for investigation of leukotriene C<inf>4</inf> synthase activity and evaluation of inhibitors

    2016, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
    Citation Excerpt :

    After release from the cell, LTC4 is processed in the extracellular space by sequential cleavage of glutamic acid and glycine residues to LTD4 and LTE4, respectively [14,15]. Cys-LTs evoke their effects via G protein-coupled receptors (CysLT1 and CysLT2) [16,17] and CysLT1 is sensitive to antagonists (e.g. montelukast or zafirlukast) used for treatment of asthma [18,19]. However, selective antagonists to CysLT2 are still lacking, and distinct studies suggest a role in other pro-inflammatory events since LTC4S deletion in mice revealed increasing endothelial permeability and exacerbating inflammatory gene expression [20,21].

  • Leukotriene Modifiers

    2008, Clinical Asthma
View all citing articles on Scopus
1

Members of the Zafirlukast Trialists Group are listed in the Acknowledgments.

View full text